pSivida (NASDAQ:PSDV) has been assigned a $5.00 price target by equities research analysts at B. Riley in a research report issued to clients and investors on Friday. The firm currently has a “buy” rating on the stock. B. Riley’s price objective points to a potential upside of 342.48% from the company’s current price.

Several other research analysts also recently commented on PSDV. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of pSivida in a report on Tuesday, September 12th. Laidlaw assumed coverage on pSivida in a report on Wednesday, November 8th. They set a “buy” rating and a $5.00 target price on the stock. ValuEngine lowered pSivida from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Northland Securities reissued a “buy” rating and issued a $10.00 price objective on shares of pSivida in a research report on Monday, December 11th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. pSivida has a consensus rating of “Buy” and a consensus price target of $7.57.

Shares of pSivida (PSDV) traded up $0.07 on Friday, reaching $1.13. The company’s stock had a trading volume of 888,161 shares, compared to its average volume of 510,891. pSivida has a 52-week low of $1.02 and a 52-week high of $2.45.

pSivida (NASDAQ:PSDV) last announced its earnings results on Tuesday, November 7th. The company reported ($0.15) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.15). The firm had revenue of $0.39 million for the quarter, compared to the consensus estimate of $0.74 million. pSivida had a negative return on equity of 139.56% and a negative net margin of 226.31%. equities analysts anticipate that pSivida will post -0.58 earnings per share for the current fiscal year.

An institutional investor recently raised its position in pSivida stock. Renaissance Technologies LLC lifted its holdings in pSivida Corp. (NASDAQ:PSDV) by 6.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 963,043 shares of the company’s stock after acquiring an additional 56,043 shares during the period. Renaissance Technologies LLC owned approximately 2.82% of pSivida worth $1,656,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 9.70% of the company’s stock.

WARNING: This report was originally reported by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at

pSivida Company Profile

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Analyst Recommendations for pSivida (NASDAQ:PSDV)

Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with's FREE daily email newsletter.